ReviewAIDS (London, England)2022
SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment.
Review in AIDS (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Leveraging remnant viral load samples for SARS-CoV-2 antibody seroprevalence trends among PLHIV in Kenya, February 2021-October 2022: a cross-sectional surveillance survey.BMJ public health · 2026Article
- Estimating risk of acquiring SARS-COV2 infection in treatment-experienced PLWH: A case-control study.Global epidemiology · 2025Article
- A cross-section study of the relationship between lifestyles and severity of COVID-19 symptoms in people living with HIV.Scientific reports · 2025Article
- Macrovascular Function in People with HIV After Recent SARS-CoV-2 Infection.Journal of vascular diseases · 2025Article
- Using multilevel modeling to assess the association between disruption in clinical services during the COVID-19 pandemic and loss of viral suppression among persons with HIV in Washington, DC.Discover public health · 2025Article
- SARS-CoV-2 seroprevalence among people living with HIV in the German HIV-1 Seroconverter Cohort, 2020-2022.BMC infectious diseases · 2024Article
- Clinical Outcomes of Coronavirus Disease 2019 in People Living With Human Immunodeficiency Virus in South Korea: A Nationwide Population-Based Cohort Study.Influenza and other respiratory viruses · 2024Article
- Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV.BMC microbiology · 2024Article
- Article
- Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.Transfusion · 2023Article
- Review
- Impact of COVID-19 on the Care of Patients with HIV Infection.Journal of clinical medicine · 2023Article
- COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa.Journal of the International AIDS Society · 2023Article
- Living with HIV and Getting Vaccinated: A Narrative Review.Vaccines · 2023Review
- Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?Current HIV/AIDS reports · 2023Review
- B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV.Communications medicine · 2023Article
- Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.AIDS (London, England) · 2022Article
- Incidence and severity of COVID-19 in adults with and without HIV diagnosis.Journal of internal medicine · 2022Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The relative susceptibility of people with HIV (PWH) to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is debated. Numerous studies have been published with apparently contradictory findings, but comparisons are difficult because they have been conducted in populations with different characteristics (e.g. age, prevalence comorbidities) and have used different comparison groups (e.g. HIV-negative cohorts, coronavirus disease 2019 (COVID-19) hospitalized patients, general population), and because of challenges to measure the most important confounders. Here, we review the evidence regarding risk and severity of SARS-CoV-2 infection in PWH compared with persons without HIV. Publications originate largely from high-income settings where the majority of the PWH are on antiretroviral therapy (ART). Despite early evidence supporting higher frequency of SARS-CoV-2 testing in PWH on ART, HIV infection is not associated with SARS-CoV-2 infection, once confounding by socioeconomic characteristic is taken into account. Most publications identify increased COVID-19 severity in PWH compared with people without HIV from the general population or compared with COVID-19 hospitalized patients. The only study with an adequate comparison group to reduce confounding, has not identified differences in COVID-19 disease severity by HIV. Publications consistently identify that COVID-19 severity in PWH is not homogeneous and increases with age and baseline comorbidities. As PWH have a higher prevalence of comorbidities than people without HIV, examining their respective contribution to poor health outcomes is not straight forward as comorbidities could mediate the effect of HIV on COVID-19 outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.